Retrieve available abstracts of 84 articles: HTML format
Single Articles
May 2025
KARTHIGEYAN KP, Connors M, Binuya CR, Gross M, et al A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits
humoral immunity similar to that of postfusion gB in mice.
J Virol. 2025 May 8:e0217824. doi: 10.1128/jvi.02178. PubMedAbstract available
LUGANO D, Mwangi K, Mware B, Kibet G, et al Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and
non-vaccinated patients from the Kenyan population.
J Virol. 2025 May 6:e0048225. doi: 10.1128/jvi.00482. PubMedAbstract available
April 2025
LE CTT, Kim K-H, Raha JR, Bhatnagar N, et al Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing
cross-lineage protection by supplementing inactivated split vaccination.
J Virol. 2025 Apr 23:e0229424. doi: 10.1128/jvi.02294. PubMedAbstract available
LI Y, Yang S, Qian J, Liu S, et al Molecular characteristics of the immune escape of coronavirus PEDV under the
pressure of vaccine immunity.
J Virol. 2025 Apr 16:e0219324. doi: 10.1128/jvi.02193. PubMedAbstract available
THIONO DJ, Samaras D, Phan TTN, Zhu DR, et al Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing
antibody response to all E-domains.
J Virol. 2025 Apr 16:e0022925. doi: 10.1128/jvi.00229. PubMedAbstract available
KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific
CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290. PubMedAbstract available
LOU Y-N, Sun M-X, Li K, Xiong X-C, et al A single residue in domain II of envelope protein of yellow fever virus is
critical for neutralization sensitivity.
J Virol. 2025;99:e0177024. PubMedAbstract available
CHENTOUFI AA, Prakash S, Vahed H, Karan S, et al A tissue-targeted prime/pull/keep therapeutic herpes simplex virus vaccine
protects against recurrent ocular herpes infection and disease in HLA-A*0201
transgenic rabbits.
J Virol. 2025 Apr 10:e0013525. doi: 10.1128/jvi.00135. PubMedAbstract available
March 2025
BLASS E, Colarusso A, Aid M, Larocca RA, et al Early spatiotemporal evolution of the immune response elicited by adenovirus
serotype 26 vector vaccination in mice.
J Virol. 2025 Mar 31:e0024725. doi: 10.1128/jvi.00247. PubMedAbstract available
OOM AL, Wilson KK, Yonatan M, Rettig S, et al The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity
MPXV-specific antibody response.
J Virol. 2025 Mar 31:e0025325. doi: 10.1128/jvi.00253. PubMedAbstract available
JANA ID, Kanjo K, Roy S, Bhasin M, et al Early 2022 breakthrough infection sera from India target the conserved cryptic
class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051. PubMedAbstract available
LI P, Faraone JN, Hsu CC, Chamblee M, et al Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC
variant in immune evasion, cell-cell fusion, and spike stability.
J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242. PubMedAbstract available
BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1)
elicits protective and long-lasting immunity in nonhuman primates.
J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990. PubMedAbstract available
BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as
a single dose primer and booster against SARS-CoV-2 variants.
J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989. PubMedAbstract available
MLINGO TAM, Theron J, Mokoena NB Plasmid DNA-based reverse genetics as a platform for manufacturing of bluetongue
vaccine.
J Virol. 2025 Mar 6:e0013925. doi: 10.1128/jvi.00139. PubMedAbstract available
HU H, Zhang Y, Zheng H, Zhao X, et al Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2
subunit vaccine by inducing dendritic cell-dependent germinal center response.
J Virol. 2025 Mar 4:e0232324. doi: 10.1128/jvi.02323. PubMedAbstract available
KARL V, Hofmann M, Thimme R Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.
J Virol. 2025 Mar 3:e0135024. doi: 10.1128/jvi.01350. PubMedAbstract available
February 2025
ABBO SR, Yan K, Geertsema C, Hick TAH, et al Virus-like particle vaccine with authentic quaternary epitopes protects against
Zika virus-induced viremia and testicular damage.
J Virol. 2025 Feb 27:e0232224. doi: 10.1128/jvi.02322. PubMedAbstract available
KEEP S, Foldes K, Dowgier G, Freimanis G, et al Recombinant infectious bronchitis virus containing mutations in non-structural
proteins 10, 14, 15, and 16 and within the macrodomain provides complete
protection against homologous challenge.
J Virol. 2025 Feb 27:e0166324. doi: 10.1128/jvi.01663. PubMedAbstract available
LI W, Hangalapura BN, van den Elzen P, van den Born E, et al Spike gene variability in porcine epidemic diarrhea virus as a determinant for
virulence.
J Virol. 2025 Feb 26:e0216524. doi: 10.1128/jvi.02165. PubMedAbstract available
CHEN C-X, Wang X, Su W, Tian Y, et al Changes in the dynamic characteristics of G-protein can alter the
immune-protection efficacy of rabies virus vaccine.
J Virol. 2025 Feb 21:e0195424. doi: 10.1128/jvi.01954. PubMedAbstract available
PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al Diversifying T-cell responses: safeguarding against pandemic influenza with
mosaic nucleoprotein.
J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867. PubMedAbstract available
January 2025
SAMAAN P, Korosec CS, Budylowski P, Chau SLL, et al mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-gamma and IL-2 T-cell responses
are predictive of serological neutralization and are transiently enhanced by
pre-existing cross-reactive immunity.
J Virol. 2025 Jan 31:e0168524. doi: 10.1128/jvi.01685. PubMedAbstract available
ZHAO B, Sun Z, Wang S, Shi Z, et al Structural basis of different neutralization capabilities of monoclonal
antibodies against H7N9 virus.
J Virol. 2025;99:e0140024. PubMedAbstract available
SADLER HL, Rijal P, Tan TK, Townsend ARM, et al A locally administered single-cycle influenza vaccine expressing a non-fusogenic
stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody
immunity.
J Virol. 2025 Jan 27:e0033124. doi: 10.1128/jvi.00331. PubMedAbstract available
KENNEDY PGE, Grose C Insights into pathologic mechanisms occurring during serious adverse events
following live zoster vaccination.
J Virol. 2025 Jan 17:e0181624. doi: 10.1128/jvi.01816. PubMedAbstract available
NAGHIBOSADAT M, Babuadze GG, Pei Y, Hurst J, et al Vaccination against SARS-CoV-2 provides low-level cross-protection against common
cold coronaviruses in mouse and non-human primate animal models.
J Virol. 2025 Jan 16:e0139024. doi: 10.1128/jvi.01390. PubMedAbstract available
DSOUZA L, Pant A, Pope B, Yang Z, et al Vaccinia growth factor-dependent modulation of the mTORC1-CAD axis upon nutrient
restriction.
J Virol. 2025 Jan 16:e0211024. doi: 10.1128/jvi.02110. PubMedAbstract available
December 2024
LV H, Teo QW, Lee C-CD, Liang W, et al Differential antigenic imprinting effects between influenza H1N1 hemagglutinin
and neuraminidase in a mouse model.
J Virol. 2024 Dec 5:e0169524. doi: 10.1128/jvi.01695. PubMedAbstract available
November 2024
LI C, Culhane MR, Schroeder DC, Cheeran MC-J, et al Quantifying the impact of vaccination on transmission and diversity of influenza
A variants in pigs.
J Virol. 2024 Nov 12:e0124524. doi: 10.1128/jvi.01245. PubMedAbstract available
JIMENEZ-CABELLO L, Utrilla-Trigo S, Rodriguez-Sabando K, Carra-Valenzuela A, et al Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full
protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.
J Virol. 2024 Nov 7:e0168724. doi: 10.1128/jvi.01687. PubMedAbstract available
CHEN D, Zhang W, Xiao B, Xu B, et al Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and
XBB reinfection risk.
J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285. PubMedAbstract available
DAI W, Xing M, Sun L, Lv L, et al Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and
humoral immune responses in a TLR9- and type I IFN-dependent pathway.
J Virol. 2024 Nov 4:e0169924. doi: 10.1128/jvi.01699. PubMedAbstract available
October 2024
PANT A, Brahim Belhaouari D, Dsouza L, Yang Z, et al Stimulation of neutral lipid synthesis via viral growth factor signaling and ATP
citrate lyase during vaccinia virus infection.
J Virol. 2024 Oct 30:e0110324. doi: 10.1128/jvi.01103. PubMedAbstract available
CAILLAVA AJ, Alfonso V, Tejerina Cibello M, Demaria MA, et al A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2
envelope confers protection against challenge in mice.
J Virol. 2024 Oct 23:e0101724. doi: 10.1128/jvi.01017. PubMedAbstract available
ZHANG D, Xie Y, Liao Q, Jiao Z, et al Development of a safe and broad-spectrum attenuated PEDV vaccine candidate by S2
subunit replacement.
J Virol. 2024 Oct 15:e0042924. doi: 10.1128/jvi.00429. PubMedAbstract available
WANG W, Bhushan G, Paz S, Stauft CB, et al Human and hamster sera correlate well in identifying antigenic drift among
SARS-CoV-2 variants, including JN.1.
J Virol. 2024 Oct 4:e0094824. doi: 10.1128/jvi.00948. PubMedAbstract available
DO THT, Wille M, Wheatley AK, Koutsakos M, et al Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution
of influenza B virus hemagglutinin and neuraminidase.
J Virol. 2024 Oct 3:e0118624. doi: 10.1128/jvi.01186. PubMedAbstract available
September 2024
HAMELE CE, Luo Z, Leonard RA, Spurrier MA, et al Headless hemagglutinin-containing influenza viral particles direct immune
responses toward more conserved epitopes.
J Virol. 2024 Sep 26:e0116624. doi: 10.1128/jvi.01166. PubMedAbstract available
LOES AN, Tarabi RAL, Huddleston J, Touyon L, et al High-throughput sequencing-based neutralization assay reveals how repeated
vaccinations impact titers to recent human H1N1 influenza strains.
J Virol. 2024 Sep 24:e0068924. doi: 10.1128/jvi.00689. PubMedAbstract available
SONG X, Li Y, Wang C, Zhao Y, et al Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV
heterologous strains with low cross-protection.
J Virol. 2024 Sep 10:e0130924. doi: 10.1128/jvi.01309. PubMedAbstract available
AGRAWAL P, Knudsen ML, MacCamy A, Hurlburt NK, et al Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key
glycan barriers on HIV-1 Env.
J Virol. 2024 Sep 6:e0074424. doi: 10.1128/jvi.00744. PubMedAbstract available
SOUDANI N, Bricker TL, Darling T, Seehra K, et al Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of
SARS-CoV-2 in Syrian hamsters.
J Virol. 2024 Sep 4:e0052824. doi: 10.1128/jvi.00528. PubMedAbstract available
August 2024
YING B, Liang C-Y, Desai P, Scheaffer SM, et al Ipsilateral or contralateral boosting of mice with mRNA vaccines confers
equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
J Virol. 2024 Aug 28:e0057424. doi: 10.1128/jvi.00574. PubMedAbstract available
GOODWIN E, Gibbs JS, Yewdell JW, Eisenlohr LC, et al Influenza virus antibodies inhibit antigen-specific de novo B cell responses in
mice.
J Virol. 2024 Aug 28:e0076624. doi: 10.1128/jvi.00766. PubMedAbstract available
WANG G, Verma AK, Guan X, Bu F, et al Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and
MERS-CoV challenge.
J Virol. 2024 Aug 27:e0037624. doi: 10.1128/jvi.00376. PubMedAbstract available
UNO N, Ebensen T, Guzman CA, Ross TM, et al Intranasal administration of octavalent next-generation influenza vaccine elicits
protective immune responses against seasonal and pre-pandemic viruses.
J Virol. 2024 Aug 22:e0035424. doi: 10.1128/jvi.00354. PubMedAbstract available
MOSS WJ, Griffin DE What's going on with measles?
J Virol. 2024;98:e0075824. PubMedAbstract available
LI J, Xiao L, Chen Z, Fan L, et al A spike-based mRNA vaccine that induces durable and broad protection against
porcine deltacoronavirus in piglets.
J Virol. 2024 Aug 19:e0053524. doi: 10.1128/jvi.00535. PubMedAbstract available
MU Z, Whitley J, Martik D, Sutherland L, et al Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin
nanoparticle designs.
J Virol. 2024 Aug 13:e0013724. doi: 10.1128/jvi.00137. PubMedAbstract available
July 2024
WIGGINS KB, Winston SM, Reeves IL, Gaevert J, et al rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective
and durable adaptive immune response with a single dose.
J Virol. 2024 Jul 30:e0078124. doi: 10.1128/jvi.00781. PubMedAbstract available
NELSON GW, van Duijn J, Yuki Y, Pau MG, et al Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine
regimen by HLA class I alleles.
J Virol. 2024 Jul 24:e0028124. doi: 10.1128/jvi.00281. PubMedAbstract available
LINGEMANN M, Amaro-Carambot E, Lamirande EW, Pierson TC, et al Simultaneous quantitation of neutralizing antibodies against all four dengue
virus serotypes using optimized reporter virus particles.
J Virol. 2024;98:e0068124. PubMedAbstract available
PORTUGAL R, Goldswain H, Moore R, Tully M, et al Six adenoviral vectored African swine fever virus genes protect against fatal
disease caused by genotype I challenge.
J Virol. 2024;98:e0062224. PubMedAbstract available
KOTAKI T, Kanai Y, Onishi M, Minami S, et al Generation of single-round infectious rotavirus with a mutation in the
intermediate capsid protein VP6.
J Virol. 2024;98:e0076224. PubMedAbstract available
MCMILLEN CM, Megli C, Radisic R, Skvarca LB, et al Vaccine strains of Rift Valley fever virus exhibit attenuation at the
maternal-fetal placental interface.
J Virol. 2024 Jul 17:e0098324. doi: 10.1128/jvi.00983. PubMedAbstract available
ZHANG L, Yu R, Wang L, Zhang Z, et al Serial cell culture passaging in vitro led to complete attenuation and changes in
the characteristic features of a virulent porcine deltacoronavirus strain.
J Virol. 2024 Jul 16:e0064524. doi: 10.1128/jvi.00645. PubMedAbstract available
RICHARDSON SI, Mzindle N, Motlou T, Manamela NP, et al SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcgammaRIIIa signaling and
neutralization than BA.1, in the context of hybrid immunity.
J Virol. 2024 Jul 2:e0067824. doi: 10.1128/jvi.00678. PubMedAbstract available
June 2024
ZHU J, Wang Z, Li Y, Zhang Z, et al Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior
protection against lethal SARS-CoV-2 challenge in mice.
J Virol. 2024 Jun 14:e0052124. doi: 10.1128/jvi.00521. PubMedAbstract available
BOOPATHY AV, Nekkalapudi A, Sung J, Schulha S, et al Flt3 agonist enhances immunogenicity of arenavirus vector-based simian
immunodeficiency virus vaccine in macaques.
J Virol. 2024 Jun 3:e0029424. doi: 10.1128/jvi.00294. PubMedAbstract available
LU J, Liu J, Wu Y, He X, et al A full-length glycoprotein mRNA vaccine confers complete protection against
severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective
effects against bandaviruses.
J Virol. 2024 Jun 3:e0076924. doi: 10.1128/jvi.00769. PubMedAbstract available
May 2024
CARTER DM, Darby CA, Lefoley BC, Crevar CJ, et al Correction for Carter et al., "Design and Characterization of a Computationally
Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses".
J Virol. 2024 May 31:e0181323. doi: 10.1128/jvi.01813. PubMed
DOETS K, Pijlman GP Subgenomic flavivirus RNA as key target for live-attenuated vaccine development.
J Virol. 2024 May 29:e0010023. doi: 10.1128/jvi.00100. PubMedAbstract available
HASHIZUME M, Takashima A, Iwasaki M An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
J Virol. 2024 May 20:e0057824. doi: 10.1128/jvi.00578. PubMedAbstract available
April 2024
THORESEN D, Matsuda K, Urakami A, Ngwe Tun MM, et al A tetravalent dengue virus-like particle vaccine induces high levels of
neutralizing antibodies and reduces dengue replication in non-human primates.
J Virol. 2024 Apr 22:e0023924. doi: 10.1128/jvi.00239. PubMedAbstract available
FAN Y-C, Chen J-M, Chen Y-Y, Ke Y-D, et al Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis
virus envelope protein is(are) important to elicit protective immunity.
J Virol. 2024;98:e0177323. PubMedAbstract available
PEREZ DR A devastating blow: personal reflections on Argentina's scientific decline.
J Virol. 2024 Apr 16:e0054924. doi: 10.1128/jvi.00549. PubMedAbstract available
ISHIMARU H, Nishimura M, Shigematsu H, Marini MI, et al Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a
conserved subdomain 1 of the spike protein.
J Virol. 2024 Apr 16:e0041624. doi: 10.1128/jvi.00416. PubMedAbstract available
TANG X, Li S, Zhou J, Bian X, et al Recombinant bivalent subunit vaccine combining truncated VP4 from P[7] and P[23]
induces protective immunity against prevalent porcine rotaviruses.
J Virol. 2024 Apr 9:e0021224. doi: 10.1128/jvi.00212. PubMedAbstract available
QUADIRI A, Prakash S, Dhanushkodi NR, Singer M, et al Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the
ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral
local tissue-resident and effector memory CD4(+) and CD8(+) T cells and protects
against recurrent
J Virol. 2024 Apr 8:e0159623. doi: 10.1128/jvi.01596. PubMedAbstract available
MANTEL N, Piras-Douce F, Chautard E, Marcos-Lopez E, et al Cynomolgus macaques as a translational model of human immune responses to yellow
fever 17D vaccination.
J Virol. 2024 Apr 3:e0151623. doi: 10.1128/jvi.01516. PubMedAbstract available
BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2
spike protein brought to phase I/II clinical trials: candidate selection in a
preclinical murine model.
J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693. PubMedAbstract available
NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2
spike protein brought to phase I/II clinical trials: protection of African green
monkeys from COVID-19 disease.
J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762. PubMedAbstract available
ZHU Z, Han Y, Gong M, Sun B, et al Establishment of replication-competent vesicular stomatitis virus recapitulating
SADS-CoV entry.
J Virol. 2024 Apr 1:e0195723. doi: 10.1128/jvi.01957. PubMedAbstract available
March 2024
WU K, Hou YJ, Makrinos D, Liu R, et al Characterization of humoral and cellular immunologic responses to an mRNA-based
human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
J Virol. 2024 Mar 25:e0160323. doi: 10.1128/jvi.01603. PubMedAbstract available
NUNBERG JH, Westover JB, York J, Jung KH, et al Restoration of virulence in the attenuated Candid#1 vaccine virus requires
reversion at both positions 168 and 427 in the envelope glycoprotein GPC.
J Virol. 2024 Mar 20:e0011224. doi: 10.1128/jvi.00112. PubMedAbstract available
MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al The varying extent of humoral and cellular immune responses to either vector- or
RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent
of infection.
J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912. PubMedAbstract available
February 2024
GEORGANA I, Scutts SR, Gao C, Lu Y, et al Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus
protein C4.
J Virol. 2024 Feb 27:e0148523. doi: 10.1128/jvi.01485. PubMedAbstract available
JOSHI VR, Claiborne DT, Pack ML, Power KA, et al A VRC13-like bNAb response is associated with complex escape pathways in HIV-1
envelope.
J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720. PubMedAbstract available
KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein
among influenza D virus lineages revealed using epitope mapping.
J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908. PubMedAbstract available
SHINGAI M, Iida S, Kawai N, Kawahara M, et al Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon
influenza virus infection by subtraction of the background antibody repertoire.
J Virol. 2024 Feb 7:e0199523. doi: 10.1128/jvi.01995. PubMedAbstract available
LI H, Sun H, Tao M, Han Q, et al Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin
protein confers broad protection against H5Ny influenza viruses.
J Virol. 2024 Feb 2:e0112923. doi: 10.1128/jvi.01129. PubMedAbstract available
HSIEH M-S, Hsu C-W, Liao H-C, Lin C-L, et al SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against
various SARS-CoV-2 variants in hamsters.
J Virol. 2024 Feb 1:e0154623. doi: 10.1128/jvi.01546. PubMedAbstract available
January 2024
ROWE T, Davis W, Wentworth DE, Ross T, et al Differential interferon responses to influenza A and B viruses in primary ferret
respiratory epithelial cells.
J Virol. 2024 Jan 31:e0149423. doi: 10.1128/jvi.01494. PubMedAbstract available